| Ticker Symbol: | IDRA |
|---|---|
| Exchange: | NASD |
| Contact Info: | 167 Sidney Street Cambridge MA 02139 617 679-5500 |
| CEO/President: | Sudhir Agrawal |
| Industry: | Medical - Biomedical / Standard Industry Code: 2836 |
| Description: | Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera\'s proprietary drug candidates are designed to modulate Toll-like Receptors, the body\'s first line of immune defense. Idera\'s pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances. |
| Shares Outstanding: | 22,950 (000) | Market Value: | 183,820 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 14.25% | Number of Inst.Shareholders: | 13.90% |
| Last Quarter Sales: | 7.50 ($Mil.) | Last Quarter Net Income: | 1.98 ($Mil.) |
| Last Quarter EPS: | 0.08 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -0.18 | |
| Most Recent Split: | 1-8 on 06/30/06 | Annual Dividend Rate: | 0 |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |

| AMGEN | +12.60 | 58.23 | |
| GILEAD SCIENCES | -1.00 | 46.92 | |
| CELGENE CP | -10.00 | 58.86 | |
| BIOGEN IDEC INC | -31.90 | 43.52 | |
| AMYLIN PHARMA I | -85.70 | 6.41 |
